---
title: "Sarepta rises on quarterly double-line beat"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295022420.md"
description: "Sarepta Therapeutics (SRPT) shares rose ~3% in after-hours trading following Q2 results that beat estimates on both earnings and revenue. Non-GAAP EPS was $0.64, while revenue reached $401.3M, despite a 34% year-over-year decline attributed to lower sales of Elevidys."
datetime: "2026-08-05T22:03:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295022420.md)
  - [en](https://longbridge.com/en/news/295022420.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295022420.md)
generator: "portal-rs"
---

# Sarepta rises on quarterly double-line beat

Sarepta Therapeutics (SRPT) is up ~3% in after-hours trading Wednesday after posting Q2 financial results that beat on both lines. Q2 Non-GAAP EPS of $0.64 compares to $2.02 in the year-ago period. Though a beat, revenue of $401.3M marked a ~34% year-over-year decline. Sarepta noted the significant revenue drop is due to lower Elevidys (delandistro...

### Related Stocks

- [SRPT.US](https://longbridge.com/en/quote/SRPT.US.md)
- [SRPU.US](https://longbridge.com/en/quote/SRPU.US.md)

## Related News & Research

- [Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)](https://longbridge.com/en/news/295099820.md)
- [DataMEDS AI reports Q2 results](https://longbridge.com/en/news/296319297.md)
- [Grounded Lithium reports Q2 results](https://longbridge.com/en/news/296441438.md)
- [BUZZ-Jack Henry jumps after quarterly profit, revenue top estimates](https://longbridge.com/en/news/296385159.md)
- [Gene Munster on Meta Stock Slide: Teen Safety, Social Media Addiction Woes Are Just the 'Tip of The Iceberg'](https://longbridge.com/en/news/296302745.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**